NCT05688371

Brief Summary

The treatment of perioperative pain in children has been a topic of great interest to pediatricians, pediatric surgeons, and anesthesiologists for many years. Opioids are the most common analgesics used to manage acute postoperative pain in children and adults

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Feb 2023

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 25, 2022

Completed
24 days until next milestone

First Posted

Study publicly available on registry

January 18, 2023

Completed
14 days until next milestone

Study Start

First participant enrolled

February 1, 2023

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2024

Completed
Last Updated

September 25, 2024

Status Verified

March 1, 2024

Enrollment Period

1.7 years

First QC Date

December 25, 2022

Last Update Submit

September 23, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Post-operative pain intensity evaluation at (0,1, 2,6,12, 24h).

    visual analogue score consists of a straight 10 cm line with the end points defining extreme limits between (0) no pain and (10) worst pain, the score is determined by measuring the distance between no pain and worst pain.

    24 hour

Secondary Outcomes (4)

  • Total morphine consumption in 24h postoperative.

    24 hour

  • sedation

    24 hour

  • respiratory depression

    24 hour

  • nausea vomiting

    24 hour

Study Arms (2)

standard dose morphine

ACTIVE COMPARATOR

children will receive 0.05 mg morphine /kg.as a bolus dose dissolved in 50 ml normal saline and 10 microgram/kg continuous infusion

Drug: standard dose morphine

low dose morphine and dexmedetomidine

ACTIVE COMPARATOR

children will receive 0.02 mg morphine /kg bolus dose plus 0.2 µg/kg dexmedetomidine dissolved in 50 ml normal saline and10 microgram/kg continuous infusion .

Drug: low dose morphine plus dexmedetomidine

Interventions

Receiving 0.05 mg morphine/kg as a bolus.

Also known as: morphine sulphate
standard dose morphine

Receiving 0.02 mg morphine/kg as a bolus dose + 0.2 microgram/kg dexmedetomidine

Also known as: precedex
low dose morphine and dexmedetomidine

Eligibility Criteria

Age8 Years - 12 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • ASA I \& II of both sex.
  • Age between 8 and 12 years.
  • Patients scheduled for exploration surgery under general anesthesia.

You may not qualify if:

  • Parents refused to give consent.
  • Patients with history of allergy to morphine or dexmedetomidine.
  • Mental disorders.
  • Unsuitability for extubation.
  • Comorbidities as cardiac, pulmonary and obstructive sleep apnea.
  • children with chronic opioid use for \> 3 monthes

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Benisuef University Hospital

Egypt, Egypt

RECRUITING

MeSH Terms

Interventions

MorphineDexmedetomidine

Intervention Hierarchy (Ancestors)

Morphine DerivativesMorphinansOpiate AlkaloidsAlkaloidsHeterocyclic CompoundsHeterocyclic Compounds, Bridged-RingHeterocyclic Compounds, 4 or More RingsHeterocyclic Compounds, Fused-RingPhenanthrenesPolycyclic Aromatic HydrocarbonsPolycyclic CompoundsImidazolesAzolesHeterocyclic Compounds, 1-Ring

Study Officials

  • Mariana abdelsayed Mansour, Lecturer

    Benisuef university hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Mariana abdelsayed Mansour, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Benisuef university

Study Record Dates

First Submitted

December 25, 2022

First Posted

January 18, 2023

Study Start

February 1, 2023

Primary Completion

October 1, 2024

Study Completion

October 1, 2024

Last Updated

September 25, 2024

Record last verified: 2024-03

Locations